GoodRx Offers Discounts of Up to 43% On Fertility Treatments
May 22 2024 - 9:00AM
Business Wire
In 2023, Americans saved over $6 million on
fertility medications using GoodRx
GoodRx, the leading destination for prescription savings in the
U.S., today announced it is offering discounts of up to 43% on
fertility treatments based on the best available GoodRx price,1
including savings on generic and brand-name medications used during
every phase of the in vitro fertilization (IVF) process. These
discounts can help manage the high costs that families and
individuals face when trying to expand their families.
Cost is one of the major challenges patients face during their
fertility treatment. A single cycle of IVF can range from $15,000
to $30,000 or more on average. Much of this cost is driven by the
multiple medications needed during an entire IVF cycle, some of
which are only available to purchase as individual doses. Plus,
many patients will need to go through more than one IVF cycle,
multiplying their treatment expenses. While employers are
increasingly adding fertility and family forming benefits, for
many, insurance rarely covers the full cost of treatment, leaving
patients to either shoulder a large financial burden or forgo
treatment altogether.
“Hundreds of thousands of people every year are faced with an
incredibly challenging decision: do I reevaluate my plans to expand
my family, or pay thousands of dollars to pursue fertility
treatments? GoodRx is here to relieve some of that financial burden
and take some of the stress out of the reproductive journey,” said
Dorothy Gemmell, Chief Commercial Officer, GoodRx. “Through savings
on both generic and brand-name medications, GoodRx helps users
afford their fertility treatments so fewer people have to choose
between their future and their finances.”
Below is a sampling of the medication discounts available for
each phase of IVF: Suppression, Stimulation, Triggering, and
Implantation
Drug Name
Out of Pocket Package
Price*
GoodRx Price**
Avg % Savings with
GoodRx
Suppression
Fyremadel
$105
$52
50%
Ganirelix
$260
$67
74%
Leuprolide
$868
$115
87%
Stimulation
Clomid
$90
$68
25%
Clomiphene
$75
$30
60%
Letrozole
$330
$22
93%
Triggering
Novarel
$228
$159
30%
Ovidrel
$293
$221
25%
Pregnyl
$172
$122
29%
Implantation
Crinone
$678
$235
37%
Endometrin
$399
$289
28%
Progesterone
$50 - $90
$13 - $23
55% - 82%
*Price is based on the smallest unit of the medication that a
patient can purchase; prices will vary based on how many units are
required for the number of doses needed. **GoodRx prices are based
on the lowest available price as of April 2024.
Learn more from trusted doctors, pharmacists and health
experts
Fertility medications and the IVF process can be complicated and
hard to understand. To further support consumers who are on their
fertility journey, or simply looking to learn more, GoodRx has
created the GoodRx Fertility Hub, which offers credible, timely,
and actionable information to help people learn more about the
fertility process, get information about common concerns, uncover
treatment options, and access significant savings. Each article is
researched and written by a team of editorial experts, and clinical
content is written and reviewed by a team of medical experts that
includes physicians, pharmacists, and more.
To find savings and trusted health information, download the
GoodRx app or go to https://www.goodrx.com/go/fertility.
About GoodRx
GoodRx is the leading destination for prescription savings in
the U.S. We offer consumers free access to transparent and lower
prices for generic and brand medications, as well as comprehensive
healthcare research and information. We also equip healthcare
professionals with efficient ways to find and prescribe affordable
medications. Since 2011, GoodRx has helped consumers save nearly
$75 billion and is one of the most downloaded medical apps over the
past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding consumer savings; the benefits of our
offerings to consumers and GoodRx; and our plans, expectations and
objectives. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, risks
relating to our ability to attract and retain talent and the
important factors discussed under the caption “Risk Factors” in our
Annual Report on Form 10-K for the year ended December 31, 2023,
and our other filings with the SEC. These factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change.
________________________________ 1 Based on the best available
GoodRx price available at participating pharmacies as of April
2024.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522443600/en/
Media Contact press@goodrx.com
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Sep 2023 to Sep 2024